Nasus Pharma (NSRX) Stock Analysis

What Nasus Pharma does

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Key metrics

ETFs linked to NSRX

Broad-market and Healthcare sector ETFs an investor holding Nasus Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NSRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Nasus Pharma?

Nasus Pharma trades under the ticker NSRX on AMEX.

Which exchange is NSRX listed on?

NSRX is listed on AMEX.

What sector does Nasus Pharma operate in?

Nasus Pharma is classified in the Healthcare sector (Medical - Pharmaceuticals industry).

How can PortView help analyze NSRX in a portfolio?

PortView shows NSRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.